Bessemer Group
TVTX icon

Bessemer Group’s Travere Therapeutics TVTX Stock Holding History

Bessemer Group’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12K Buy
209
+54
+35% +$2.39K ﹤0.01% 2127
2026
Q1 		$5K Sell
155
-51
-25% -$1.52K ﹤0.01% 2242
2025
Q4 		$8K Sell
206
-96
-32% -$3.12K ﹤0.01% 2172
2025
Q3 		$7K Buy
302
+96
+47% +$1.8K ﹤0.01% 2073
2025
Q2 		$3K Hold
206
– – ﹤0.01% 2159
2025
Q1 		$4K Buy
206
+41
+25% +$832 ﹤0.01% 2117
2024
Q4 		$3K Hold
165
– – ﹤0.01% 2164
2024
Q3 		$2K Sell
165
-169
-51% -$1.76K ﹤0.01% 2283
2024
Q2 		$3K Buy
+334
New +$2.25K ﹤0.01% 1902
2022
Q2 		– Sell
-221
Closed -$6K – 2030
2022
Q1 		$6K Hold
221
– – ﹤0.01% 1487
2021
Q4 		$7K Hold
221
– – ﹤0.01% 1511
2021
Q3 		$5K Hold
221
– – ﹤0.01% 1522
2021
Q2 		$3K Hold
221
– – ﹤0.01% 1496
2021
Q1 		$6K Buy
+221
New +$6.11K ﹤0.01% 1381
2020
Q3 		– Sell
-99,800
Closed -$2.04M – 1659
2020
Q2 		$2.04M Buy
+99,800
New +$1.59M 0.01% 473
2019
Q4 		– Sell
-66
Closed -$1K – 1763
2019
Q3 		$1K Buy
+66
New +$1.09K ﹤0.01% 1686

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bessemer Group's TVTX Position: Q2 2026 in Review

Bessemer Group increased its Travere Therapeutics (TVTX) stake by 35% in Q2 2026, buying an estimated $2.39K and bringing the position to 209 shares worth $12K. The position accounts for ﹤0.01% of the portfolio, ranked #2127.

Bessemer Group first reported a position in TVTX in Q3 2019 and has held it in 16 quarters since. The position peaked at $2.04M in Q2 2020. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Bessemer Group held 209 shares of Travere Therapeutics worth $12K as of Q2 2026.
  • Bessemer Group bought 54 Travere Therapeutics shares in Q2 2026, an estimated $2.39K.
  • Travere Therapeutics made up ﹤0.01% of Bessemer Group's portfolio in Q2 2026, its #2127 holding.
  • Bessemer Group first reported a position in Travere Therapeutics in Q3 2019 and has held it in 16 quarters since.
  • Bessemer Group's Travere Therapeutics position peaked at $2.04M in Q2 2020.
  • 321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Bessemer Group's 13F filing for Q2 2026, filed 12 Aug 2026.